Stryker announced today that it has completed the acquisition of Inari Medical. A press release notes that the addition of Inari brings an established peripheral vascular position to Stryker in the fast-growing venous thromboembolism (VTE) segment.
“The acquisition of Inari Medical marks a significant milestone in expanding our interventional endovascular portfolio,” said Kevin Lobo, chair and chief executive officer, Stryker.
The company states that Inari’s product portfolio is “highly complementary” to Stryker’s neurovascular business and includes two novel mechanical thrombectomy solutions—the FlowTriever system for the treatment of pulmonary embolism and the ClotTriever system for thrombectomy in the peripheral vessels—as well as emerging therapies.
